Real-time data provides useful information complementary to clinical trial data, with the potential to fill knowledge gaps in the development of new therapies, particularly in the field of neuroscience.

Indeed, this lack of measurement affects clinical trials. In clinical research, these data are subjective and periodic and prevent an understanding of the etiology and associated risk factors. As a result, the scope of interventions in clinical trials remains limited.

Treatments continue to be offered without predictive biomarkers of response, which could allow more targeted treatments to be prescribed.

KLAVA improves clinical trial research by providing a range of digital biomarkers through real-time data collection.